One-Dose hope for blistering skin disease?
NCT ID NCT00525616
First seen Apr 20, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tested whether a single cycle of the drug rituximab can control bullous pemphigoid, a painful blistering skin condition. Researchers followed 18 adults for up to two years to see if the drug stopped the disease and checked for side effects. The goal was to find a treatment that reduces reliance on steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rouen University Hospital, Direction de la Recherche et de l'Innovation,
Rouen, 76031, France
Conditions
Explore the condition pages connected to this study.